NASDAQ:LPCN - Lipocine Stock Price, Forecast & News

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Lipocine Inc (NASDAQ:LPCN) released its quarterly earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.04. The specialty pharmaceutical company earned $0.17 million during the quarter. View Lipocine's Earnings History.

Lipocine is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Lipocine.

2 brokers have issued 1 year target prices for Lipocine's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Lipocine's share price to reach $2.00 in the next year. This suggests a possible upside of 331.6% from the stock's current price. View Analyst Price Targets for Lipocine.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lipocine.

News articles about LPCN stock have trended neutral on Tuesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lipocine earned a coverage optimism score of 0.3 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near term. View News Stories for Lipocine.

Some companies that are related to Lipocine include Adamis Pharmaceuticals (ADMP), Humanigen (HGEN), Annovis Bio (ANVS), Merrimack Pharmaceuticals (MACK), Pharmaxis (PXSLY), Iterum Therapeutics (ITRM), Evoke Pharma (EVOK), Jaguar Health (JAGX), Moleculin Biotech (MBRX), Citius Pharmaceuticals (CTXR), RegeneRx Biopharmaceuticals (RGRX), Generex Biotechnology (GNBT), Alimera Sciences (ALIM), Addex Therapeutics (ADDXF) and Vistagen Therapeutics (VTGN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Novavax (NVAX), Cara Therapeutics (CARA), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Actinium Pharmaceuticals (ATNM), Melinta Therapeutics (MLNT) and Ocular Therapeutix (OCUL).

Lipocine's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (7.49%) and Mercer Global Advisors Inc. ADV (0.28%). Company insiders that own Lipocine stock include Mahesh V Patel and Morgan R Brown. View Institutional Ownership Trends for Lipocine.

LPCN stock was sold by a variety of institutional investors in the last quarter, including Mercer Global Advisors Inc. ADV. Company insiders that have sold Lipocine company stock in the last year include Mahesh V Patel and Morgan R Brown. View Insider Buying and Selling for Lipocine.

LPCN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Lipocine.

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LPCN stock can currently be purchased for approximately $0.46.

Lipocine has a market capitalization of $11.77 million and generates $430,000.00 in revenue each year. The specialty pharmaceutical company earns $-11,660,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Lipocine employs 10 workers across the globe.View Additional Information About Lipocine.

The official website for Lipocine is http://www.lipocine.com/.

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]